Marshall Wace, LLP Harrow Health, Inc. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$10.0 - $21.64 $532,490 - $1.15 Million
53,249 New
53,249 $1.11 Million
Q4 2023

Feb 14, 2024
SELL
$8.1 - $16.36 $85,795 - $173,285
-10,592 Reduced 8.53%
113,534 $1.27 Million
Q3 2023

Nov 14, 2023
BUY
$14.03 - $22.08 $1.74 Million - $2.74 Million
124,126 New
124,126 $1.78 Million
Q1 2023

May 15, 2023
SELL
$13.84 - $21.46 $33,229 - $51,525
-2,401 Reduced 2.35%
99,629 $2.11 Million
Q4 2022

Feb 14, 2023
BUY
$10.28 - $14.78 $771,318 - $1.11 Million
75,031 Added 277.9%
102,030 $1.51 Million
Q3 2022

Nov 14, 2022
BUY
$6.57 - $24.88 $6,767 - $25,626
1,030 Added 3.97%
26,999 $326,000
Q2 2022

Aug 15, 2022
BUY
$5.75 - $7.74 $149,321 - $201,000
25,969 New
25,969 $189,000
Q2 2021

Aug 13, 2021
SELL
$6.68 - $11.07 $195,536 - $324,041
-29,272 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$6.26 - $11.03 $183,242 - $322,870
29,272 New
29,272 $198,000
Q2 2020

Aug 13, 2020
SELL
$3.61 - $6.47 $38,601 - $69,183
-10,693 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$3.5 - $7.31 $37,425 - $78,165
10,693 New
10,693 $41,000
Q2 2019

Aug 14, 2019
SELL
$4.2 - $8.7 $931,110 - $1.93 Million
-221,693 Closed
0 $0
Q1 2019

May 14, 2019
BUY
$4.75 - $7.1 $1.05 Million - $1.57 Million
221,693 New
221,693 $1.1 Million

Others Institutions Holding HROW

# of Institutions
178
Shares Held
21.3M
Call Options Held
845K
Put Options Held
717K
View Full List

About HARROW HEALTH, INC.

HROW Quotes by TradingView
  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $926M
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email